Lord, Abbett & Co
NTLA icon

Lord, Abbett & Co’s Intellia Therapeutics NTLA Stock Holding History

Lord, Abbett & Co’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-375,399
Closed -$19.4M – 599
2022
Q2 		$19.4M Buy
375,399
+12,649
+3% +$642K 0.07% 336
2022
Q1 		$26.4M Sell
362,750
-584,084
-62% -$49.5M 0.07% 334
2021
Q4 		$112M Sell
946,834
-103,965
-10% -$13M 0.26% 120
2021
Q3 		$141M Buy
1,050,799
+159,899
+18% +$24.2M 0.34% 82
2021
Q2 		$144M Buy
890,900
+211,759
+31% +$16.5M 0.35% 78
2021
Q1 		$54.5M Buy
+679,141
New +$45.6M 0.14% 232
2019
Q4 		– Sell
-265,382
Closed -$3.54M – 718
2019
Q3 		$3.54M Sell
265,382
-17,904
-6% -$285K 0.01% 653
2019
Q2 		$4.64M Sell
283,286
-75,742
-21% -$1.19M 0.02% 657
2019
Q1 		$6.13M Buy
359,028
+108,825
+43% +$1.62M 0.02% 633
2018
Q4 		$3.42M Buy
250,203
+85,124
+52% +$1.58M 0.01% 698
2018
Q3 		$4.72M Buy
+165,079
New +$4.8M 0.01% 740

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Lord, Abbett & Co's NTLA Position: Q3 2022 in Review

Lord, Abbett & Co sold out of Intellia Therapeutics (NTLA) in Q3 2022, closing a stake of 375,399 shares — an estimated $19.4M sold.

Lord, Abbett & Co first reported a position in NTLA in Q3 2018 and held it in 11 quarters. The position peaked at $144M in Q2 2021. 319 funds tracked by Wall St. Rank hold NTLA as of Q3 2022.

  • Lord, Abbett & Co reported no remaining Intellia Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Lord, Abbett & Co sold 375,399 Intellia Therapeutics shares in Q3 2022, an estimated $19.4M.
  • Lord, Abbett & Co first reported a position in Intellia Therapeutics in Q3 2018 and held it in 11 quarters.
  • Lord, Abbett & Co's Intellia Therapeutics position peaked at $144M in Q2 2021.
  • 319 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2022.

Based on Lord, Abbett & Co's 13F filing for Q3 2022, filed 14 Nov 2022.